TITLE

Synopsis of the National Institute for Health and Clinical Excellence Guideline for Prevention of Delirium

AUTHOR(S)
O'Mahony, Rachel; Murthy, Lakshmi; Akunne, Anayo; Young, John
PUB. DATE
June 2011
SOURCE
Annals of Internal Medicine;6/7/2011, Vol. 154 Issue 11, p746
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Description: Delirium is common, is often underrecognized, and is associated with poor outcomes and high costs. In July 2010, the National Institute for Health and Clinical Excellence released a guideline that addressed diagnosis, prevention, and management of delirium. This synopsis focuses on the main recommendations about prevention of delirium. Methods: The National Clinical Guideline Centre developed these guidelines by using standard methodology of the National Institute for Health and Clinical Excellence. A multidisciplinary guideline development group posed review questions, discussed evidence, and formulated the recommendations. To underpin the guideline, a technical team from the National Clinical Guideline Centre systematically reviewed and graded pertinent evidence identified from literature searches of studies published in English to August 2009 and performed health economic modeling. Stakeholder and public comment informed guideline development and modifications. Recommendations: Considering prevention a feasible and cost- effective health strategy, the guideline development group made 13 specific recommendations that addressed the stability of the care environment (both the care team and location) and the provision of a multicomponent intervention package tailored for persons at risk for delirium. The multicomporient intervention package included assessment and modification of key clinical factors that may precipitate delirium, including cognitive impairment or disorientation, dehydration or constipation, hypoxia, infection, immobility or limited mobility, several medications, pain, poor nutrition, sensory impairment, and sleep disturbance.
ACCESSION #
62807877

 

Related Articles

  • Opinion: Ballot box.  // GP: General Practitioner;10/8/2010, p26 

    The article presents the findings of a public opinion poll on the British government's decision to transfer drug funding decisions from the National Institute for Health and Clinical Excellence (NICE) to general practitioners (GPs).

  • Economist says NICE should approve fewer costly drugs. O'Dowd, Adrian // BMJ: British Medical Journal (International Edition);7/7/2007, Vol. 335 Issue 7609, p11 

    The article discusses a recommendation from economist Peter Smith, director of the Centre for Health Economics, at the University of York, that Great Britain's National Institute for Health and Clinical Excellence (NICE) should approve fewer costly drugs. Smith, speaking before a health select...

  • Schools and councils enlisted in war against junk food.  // Education (14637073);6/25/2010, Issue 397, p3 

    The article discusses guidelines issued by the British National Institute for Health and Clinical Excellent (NICE) urging schools and local councils to help reduce the consumption of junk food by children and youth.

  • Prescribing practice should follow NICE guidance.  // PharmacoEconomics & Outcomes News;8/21/2010, Issue 610, p5 

    The article discusses a report from the Great Britain National Health Services (NHS) National Prescribing Centre highlighting the need to review and revise medical prescription to ensure that it complies with the National Institute for Health and Clinical Excellence (NICE) guidance, improving...

  • Pre-watershed ban on food and drink ads under attack. Fernandez, Joe // Marketing Week;6/24/2010, Vol. 33 Issue 26, p5 

    The article reports on the negative criticism made by advertising bodies against the guidance issued by the National Institute for Health and Clinical Excellence (NICE) that bans all food and drink advertising before 9 p.m. in Great Britain.

  • NICE must adapt to the new NHS market. Minhas, Rubin // Pulse;10/13/2010, Vol. 70 Issue 30, p17 

    In this article, the author discusses the need for the National Institute for Health and Clinical Excellence (NICE) to confirm with the National Health Service (NHS) reforms enforced by the Department of Health in Great Britain.

  • NICE no longer recommends omalizumab for asthma . . .  // PharmacoEconomics & Outcomes News;11/24/2012, Issue 667, p14 

    The article focuses on the draft guidance of the National Institute for Health and Clinical Excellence (NICE) in Great Britain which prohibits the use of omalizumab in adults with severe, persistent allergic asthma.

  • New guidance from NICE.  // PharmacoEconomics & Outcomes News;1/26/2013, Issue 670, p2 

    The article reports that the National Institute for Health and Clinical Excellence (NICE) in Great Britain has launched a consultation on its plan to update the guidance on familial breast cancer.

  • Draft guidance from NICE recommends nalmefene . . .  // PharmacoEconomics & Outcomes News;Jul2014, Vol. 707 Issue 1, p9 

    The article reports on the decision of the British National Institute for Health and Care Excellence (NICE) to recommend nalmefene for the treatment of alcohol dependency as stated in a draft guidance.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics